Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial

BACKGROUND: A Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group. METHODS: CitAD was a r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Drye, Lea T., Spragg, David, Devanand, D. P., Frangakis, Constantine, Marano, Christopher, Meinert, Curtis L., Mintzer, Jacobo E., Munro, Cynthia A., Pelton, Gregory, Pollock, Bruce G., Porsteinsson, Anton P., Rabins, Peter V., Rosenberg, Paul B., Schneider, Lon S., Shade, David M., Weintraub, Daniel, Yesavage, Jerome, Lyketsos, Constantine G.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4051660/
https://ncbi.nlm.nih.gov/pubmed/24914549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0098426
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados